Audit: QRS - Celastrus paniculatus for Health & Longevity
Audit conducted on 17/08/2026 13:42 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every string traced: protocol doses to ER lines 313–317, timing to 325/367, gates to 271–293, markers and cadence to 389–400, qualitative items to 404–409, at-a-glance to Conclusion 427–431. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Never measured in humans” (time_3_value) and “No established target” (marker_6_target) mirror ER lines 325 and 400. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute; MAOIs stay a contraindication rather than a caution, matching ER line 271. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | No Benefit- or Risk-Modifying Factor and no Risk Mitigation Strategy is surfaced; each card draws only from its mapped ER section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, citations, expert names, NCT IDs, or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution of any kind is present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s plain, blunt register, including “Human evidence is all but empty” against ER line 429. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tight functional targets and a trackable cadence give the reader actionable leverage without overselling the evidence. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Statements are declarative (“Morning with food is the conventional choice”), not instructional. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperative or prescriptive verbs; gates and markers are stated as facts drawn from the ER. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should”, or “guidance” anywhere in the body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun appears; marker_6_target uses “the individual’s own baseline”. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Enzyme and drug-class names are spelled out in full (alanine aminotransferase, non-steroidal anti-inflammatory drugs) rather than abbreviated. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are reduced to bare facts; all mechanistic and severity clauses are stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”, “your”, “we”, or “our” in the rendered body. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a reader who will bank a baseline semen analysis and demand functional rather than laboratory reference ranges. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring cadence spanning 8 weeks to 12 months and repeat semen analysis presume that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification to a general-population “ask your doctor” register. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance weighs a replicated animal signal against an empty human record and a category contamination problem. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” / “antiaging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terms throughout (“erosive gastritis”, “Child-Pugh Class B or C cirrhosis”, “monoamine oxidase inhibitors”); no “pill” or “shot”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fifteen fixed strings verified byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variables present; the repeatable marker_#* and qualitative_item# spans are instantiated as marker_1..6 and qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Normalised diff against the template shows no change beyond filled variables, the three required display:none attributes, and repeated table/list rows; the website="evidence_review", website="audit", and website="full_review" spans, CSS, and footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the unpopulated benefit and risk tiers are governed by items 12.5 and 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Modern supplement protocol”, “Seed oil protocol”, “Standard traditional protocol”, “Half-life”, and all seven interaction labels are carried over verbatim from the ER bold labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Benefit and risk items reuse the ER subsection headings verbatim; marker names match the ER biomarker table exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan of all non-ASCII characters returns only µ, ×, en dash, and em dash — no emoji; the ER’s “⚠️ Conflicted” marker was correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Structure is unchanged from the one-page template and every section is condensed to the budget: at-a-glance 60 words, tier lists single-line, gate items stripped to bare facts. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, ahead of the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” on line 3, closing “—” on line 13; the preamble text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine values trimmed; only duration: "00:04" is quoted, which its colon requires. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: celastrus_paniculatus_2026-0825-1134_Opus_ER.md, which matches the ER’s own filename field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0817-1324, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single bare word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Celastrus paniculatus for Health & Longevity - Quick Reference Sheet”, with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Celastrus paniculatus for Health & Longevity”, matching ER frontmatter line 8. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “08/17/2026” correctly derived from qrs_creation_date 2026-0817-1324. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, identical to the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four Conclusion paragraphs (ER lines 427–433) into benefit signal, evidence gap, animal harms, and contamination. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Counted programmatically: exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: line 427 for the benefit list, 429 for the empty human record and animal harms, 431 for heavy metals. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “nerve cells”, “stomach burning”, and “brain tonic” replace clinical register throughout. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study name, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate; the contamination point is stated qualitatively. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Sourced from the “Populations who should avoid Celastrus paniculatus” list plus the MAOI contraindication in that section (ER lines 271, 285–293). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER avoid-populations are present, with the MAOI class correctly promoted from the interactions bullet where the ER calls it “an absolute contraindication”. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER rationale clause stripped (“given traditional use…”, “since no data exist on transfer into milk”, “for whom no dosing or safety data exist”); no dash-led clause remains. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | The 74-day window, the three-times-upper-limit-of-normal threshold, Child-Pugh Class B or C staging, and the 14-day MAOI washout are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names seven such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map one-to-one onto the ER interaction bullets at lines 271–283. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The “Serotonergic antidepressants” item carries only the SSRI half; the MAOI half sits in Contraindications and is not duplicated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements, each with the ER’s bold label. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every Severity, Consequence, and Mitigation clause is stripped, as is the ER’s em-dash gloss “— dementia drugs that raise acetylcholine”. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named example drugs retained, verified against the ER: sertraline/fluoxetine, diazepam/lorazepam, zolpidem/eszopiclone, donepezil/rivastigmine/galantamine, atorvastatin/rosuvastatin, diphenhydramine/doxylamine, ibuprofen/naproxen, alpha-GPC/citicoline/huperzine A, St John’s wort/5-HTP/S-adenosylmethionine, valerian/kava/melatonin. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER lists seven interaction classes, and the section is populated accordingly. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells draw from the ER “Therapeutic Protocol” bullets at lines 313–317 and 323. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three dosable forms — modern capsule, pressed oil, traditional seed titration — are the only directly actionable bullets; the remainder of the ER section is commentary on comparison, timing, and modifiers. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine fields populated; e.g. action_1 reproduces “400–500 mg of seed powder or water extract, taken once or twice daily” from ER line 315. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Onset delay, assessment horizon, and half-life — the only three timing facts the ER supplies (lines 325 and 367). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Memory and learning, the ER’s best-replicated benefit domain, leads; the assessment window and the unmeasured half-life follow as progressively less benefit-specific. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine fields populated; “14–30 days” and “single doses are ineffective” are lifted from ER lines 325 and 367. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Tiers and items correspond exactly to the ER Expected Benefits subsections at lines 131–193. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and correctly assigned. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Reduced to the bare ER subsection headings; all Magnitude paragraphs, doses, and the “⚠️ Conflicted” qualifier are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in either benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high and benefits_medium carry style="display: none" with no empty-state text, matching the ER’s “No benefit… reaches this evidence level” at lines 133 and 137. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven items map to the ER risk subsections at lines 211–255. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and correctly assigned. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare ER headings only; the 20.7%-of-193-products figure and all Magnitude detail are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high carries style="display: none" with no empty-state text, matching the ER’s “No risk reaches this evidence level” at line 213. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both come from the ER “Monitoring Protocol & Defining Success” section, lines 389–400. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six rows of the ER biomarker table are present with matching names, targets, and rationales. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces the ER cadence at lines 389–391 and 400: liver enzymes at 8 weeks, 6 months, then annually; lipids and hsCRP at 12 weeks; semen analysis banked and repeated at 6 months; metals only on source change or unexplained symptoms. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the ER’s “Qualitative markers to track alongside the labs” list at lines 402–409. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present, in ER order, as qualitative_item_1 through qualitative_item_6. |
Issues 17/08/2026 13:42
Pass rate 100.00%. No issues found.
Issues 17/08/2026 13:33
- 1.1 / 7.3 — At-A-Glance overstates animal-only harms: [at_a_glance] (line 437) asserts “Harms are animal-only”, but the ER Conclusion (ER line 429) pairs the two animal harms with “the stomach burning that users describe”, a human-reported harm.
- 1.4 / 11.1 — Intended duration is not a time-to-effect aspect: The third [time] set (lines 526–536) carries “Intended duration” and cycling facts from the ER
Discontinuation & Cyclingsection (ER lines 341, 347) rather than a time-to-effect aspect, while the ER’s third genuine time aspect — “Half-life: Never measured in humans for any constituent” (ER line 325) — is omitted. - 11.4 — time_2 label duplicates the subhead: [time_2_label] (line 512) is “Time to effect”, identical to the grid subhead at line 492, so it names no aspect; [time_2_sub] (line 519) also attributes the 4–8 week window to “judging anxiety and mood alongside memory”, which ER line 367 does not.
Fixes 17/08/2026 13:33
- 1.1 / 7.3 — At-A-Glance harms clause corrected: Replaced “Harms are animal-only — halted sperm production, reversible liver damage —” with “Animal harms: halted sperm production, reversible liver damage; plus user-reported stomach burning,” so the human-reported harm in the ER Conclusion is no longer excluded; trimmed “climbing” and “and” elsewhere to hold the summary at 60 words.
- 1.4 / 11.1 — Third time set replaced with a time-to-effect aspect: Swapped the “Intended duration / Weeks to a few months” cell (from ER
Discontinuation & Cycling) for “Half-life / Never measured in humans”, with a sub noting the 14–30 day delay implies gradual adaptation or accumulation rather than acute action (ER line 325). - 11.4 — time_2 relabelled and sub made ER-faithful: Changed [time_2_label] from “Time to effect” (a duplicate of the grid subhead) to “Assessment window”, and reworded [time_2_sub] from “judging anxiety and mood alongside memory” to “judging any response” to match ER line 367.